Organovo Holdings, Inc. (ONVO)

[WHP03]

Evercore ISI initiates coverage on Organovo Holdings (NASDAQ: ONVO) with a Buy rating and a price target of $4.50.

Analyst Ross Muken commented, "Our BUY investment thesis rests on three key revenue growth drivers that will likely lead to Organovo being the ultimate winner in the nascent bioprinting market, and they include 1) rapid market adoption of 3D printed liver and kidney tissue used in preclinical toxicity studies, 2) pharma companies partnering / collaborating with ONVO for drug development screening within these tissues, and 3) the use of 3D printed liver tissue as a therapy for patients suffering severe liver disease."

http://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Starts+Organovo+Holdings+%28ONVO%29+at+Buy/12287956.html

Ross Muken, Evercore ISI background (links):

http://www.evercore.com/team/3/all/all/bio/380/Investment-Banking/evercore-isi-team
https://www.linkedin.com/in/ross-muken-35693231
http://www.bloomberg.com/research/stocks/private/person.asp?personId=29071186&privcapId=100489358
https://www.tipranks.com/analysts/ross-muken
http://www.bizjournals.com/prnewswire/press_releases/2016/10/06/NY11285